The Food and Drug Administration will now require osteoporosis drug makers Fosamax, Boniva, Actonel, Atelvia and Reclast to clearly state how long patients can take the drug to optimize benefits and lower risks, according to a report in the Times Tribune.
The wording of the new labels is yet to be determined. There have been some patients who reported complications after taking the drugs for a certain amount of time. The recommended time period for each drug could vary.
Related Articles on Osteoporosis:
Study Finds Hip Fracture Rate Could Drop 25% With Aggressive Osteoporosis Prevention Plan
Hospital for Special Surgery Rheumatologist Explains New Osteoporosis Recommendations
Study Links Some Osteoporosis Medications to Rare Thigh Fractures
Related Articles on Osteoporosis:
Study Finds Hip Fracture Rate Could Drop 25% With Aggressive Osteoporosis Prevention Plan
Hospital for Special Surgery Rheumatologist Explains New Osteoporosis Recommendations
Study Links Some Osteoporosis Medications to Rare Thigh Fractures